Skip to content
value.today
ViraCyte, Inc. logo

ViraCyte, Inc.

🇺🇸 New Brighton, Minnesota, USABiotechnologyFounded 2018
Total raised
$151 M
2 rounds on record
Latest round
$121 M
May 2019
First round on record
Sep 2018
Today
Went public
See the company page

ViraCyte, Inc. is listed today as Kalaris Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ViraCyte, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2019$121 MNo. 2$50 to $250 million

ViraCyte, Inc.: Raise no. 2, May 2019

Investors in this round

47 investors had bought by the notice of May 22, 2019: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for ViraCyte, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$121 M of $121 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Hallal · Executive Officer, Director
  • Vikas Sinha · Executive Officer, Director
  • Ansbert Gadicke · Director
  • John Wilson · Director
  • Juan Vera · Director
  • Malcom Brenner · Director
  • Morana Jovan-Embiricos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold shown in item 13 and number of investors shown in item 14 includes $28,999,982 from 3 non-US investors.”

Signed by Vikas Sinha, President. Source: SEC Form D, newest notice filed May 22, 2019. Read the notice at the SEC.

equitySEC
Sep 2018$30 MNo. 1$10 to $50 million

ViraCyte, Inc.: Raise no. 1, Sep 2018

Investors in this round

1 investor had bought by the notice of Oct 2, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for ViraCyte, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $50 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$6,837,146 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Hallal · Executive Officer, Director
  • Vikas Sinha · Executive Officer, Director
  • Ansbert Gadicke · Director
  • John Wilson · Director
  • Juan Vera · Director
  • Malcom Brenner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Pursuant to Redeemable Preferred Stock Redemption Agreement”

Signed by David Hallal, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 2, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ViraCyte, Inc. chose not to state its revenue in its newest notice of a funding round (May 2019).

    SEC Form D · May 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2019

That is all the official record says: ViraCyte, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of ViraCyte, Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in ViraCyte, Inc.
InvestorKindAmountRoundRoleSource
Brett R. HagenPersonnot statednot statedHeld Series B preferred stock (Form 3, 2020)SEC Form 3
ElevateBio, LLCOthernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Jeroen B. Van BeekPersonnot statednot statedHeld Series B preferred stock (Form 3, 2020)SEC Form 3
John Robert WilsonPersonnot statednot statedHeld Series A-3 preferred stock, director (Form 3, 2020)SEC Form 3
Juan VeraPersonnot statednot statedHeld Series A-3 preferred stock, director (Form 3, 2020)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 47 investors.

Largest shareholders today

Institutions holding Kalaris Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ViraCyte, Inc.
NameRoleNamed in
David HallalExecutive officerMay 2019
Vikas SinhaExecutive officerMay 2019
Ansbert GadickeDirectorMay 2019
David HallalDirectorMay 2019
John WilsonDirectorMay 2019
Juan VeraDirectorMay 2019
Malcom BrennerDirectorMay 2019
Morana Jovan-EmbiricosDirectorMay 2019
Vikas SinhaDirectorMay 2019

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.